NASDAQ:MXCT MaxCyte (MXCT) Stock Price, News & Analysis → Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad) Buy MXCT with Qtrade Free MXCT Stock Alerts $3.80 -0.16 (-4.04%) (As of 04:30 PM ET) Add Compare Share Share Today's Range$3.78▼$4.1150-Day Range$3.88▼$4.7952-Week Range$2.45▼$5.55Volume569,042 shsAverage Volume636,658 shsMarket Capitalization$396.70 millionP/E RatioN/ADividend YieldN/APrice Target$8.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get MaxCyte alerts: Email Address MaxCyte MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside128.1% Upside$8.67 Price TargetShort InterestBearish3.57% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingSelling Shares$47,650 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.53) to ($0.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.42 out of 5 starsMedical Sector550th out of 910 stocksCommercial Physical Research Industry10th out of 12 stocks 3.5 Analyst's Opinion Consensus RatingMaxCyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMaxCyte has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.57% of the float of MaxCyte has been sold short.Short Interest Ratio / Days to CoverMaxCyte has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in MaxCyte has recently increased by 4.49%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMaxCyte does not currently pay a dividend.Dividend GrowthMaxCyte does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MXCT. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for MaxCyte this week, compared to 1 article on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MaxCyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $47,650.00 in company stock.Percentage Held by InsidersOnly 6.00% of the stock of MaxCyte is held by insiders.Percentage Held by Institutions68.81% of the stock of MaxCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MaxCyte are expected to grow in the coming year, from ($0.53) to ($0.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MaxCyte is -10.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MaxCyte is -10.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMaxCyte has a P/B Ratio of 1.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsPentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>> About MaxCyte Stock (NASDAQ:MXCT)MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.Read More MXCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MXCT Stock News HeadlinesMarch 29, 2024 | insidertrades.comInsider Selling: MaxCyte, Inc. (NASDAQ:MXCT) Director Sells 5,000 Shares of StockApril 10, 2024 | globenewswire.comMaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024April 23, 2024 | Behind the Markets (Ad)Pentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...April 5, 2024 | msn.comMesa Laboratories maintains quarterly dividend of $0.16April 2, 2024 | globenewswire.comMaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)March 17, 2024 | finance.yahoo.comDowngrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near TermMarch 15, 2024 | finanznachrichten.deMaxCyte, Inc: MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 GuidanceMarch 14, 2024 | finance.yahoo.comMaxCyte, Inc. (LON:MXCT) Just Reported And Analysts Have Been Cutting Their EstimatesApril 23, 2024 | Behind the Markets (Ad)Pentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...March 13, 2024 | marketwatch.comMaxCyte Shares Rise 13% After 4Q Beat, Reaffirmed GuidanceMarch 12, 2024 | globenewswire.comMaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 GuidanceMarch 12, 2024 | globenewswire.comMaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 GuidanceMarch 6, 2024 | finanznachrichten.deMaxCyte, Inc.: MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary ResultsMarch 4, 2024 | globenewswire.comMaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary ResultsMarch 4, 2024 | globenewswire.comMaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary ResultsFebruary 9, 2024 | finance.yahoo.comMaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor ConferencesJanuary 30, 2024 | finance.yahoo.comMaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for CancersJanuary 23, 2024 | markets.businessinsider.comMaxCyte Signs SPL Agreement With ImugeneJanuary 9, 2024 | msn.comWhy Cell Engineering Company MaxCyte Shares Are Up TodayJanuary 9, 2024 | seekingalpha.comCOMM, NKTX and AVIR are among after hour moversJanuary 5, 2024 | benzinga.comMaxCyte Stock (NASDAQ:MXCT) Dividends: History, Yield and DatesJanuary 3, 2024 | finance.yahoo.comMaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell PipelineJanuary 2, 2024 | finanznachrichten.deMaxCyte, Inc: MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and DirectorJanuary 2, 2024 | msn.comMaxCyte gets new CEO and PresidentJanuary 2, 2024 | finance.yahoo.comMaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and DirectorDecember 15, 2023 | finance.yahoo.comWith 74% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big gunsDecember 11, 2023 | marketwatch.comMaxCyte Names Maher Masoud CEOSee More Headlines Receive MXCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/12/2024Today4/23/2024Next Earnings (Confirmed)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryN/A Current SymbolNASDAQ:MXCT CUSIPN/A CIK1287098 Webmaxcyte.com Phone301-944-1700Fax301-944-1703Employees143Year FoundedN/APrice Target and Rating Average Stock Price Target$8.67 High Stock Price Target$11.00 Low Stock Price Target$7.00 Potential Upside/Downside+125.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,920,000.00 Net Margins-91.85% Pretax Margin-91.85% Return on Equity-15.90% Return on Assets-13.94% Debt Debt-to-Equity RatioN/A Current Ratio10.65 Quick Ratio9.97 Sales & Book Value Annual Sales$41.29 million Price / Sales9.71 Cash FlowN/A Price / Cash FlowN/A Book Value$2.23 per share Price / Book1.72Miscellaneous Outstanding Shares104,396,000Free Float98,132,000Market Cap$400.88 million OptionableOptionable Beta1.34 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Maher Masoud (Age 48)President, CEO, Secretary & Director Comp: $612.07kMr. Douglas Arthur Doerfler (Age 68)Founder Comp: $1.2MMr. Douglas J. Swirsky CFA (Age 55)CPA, Chief Financial Officer Mr. Jay GelfmanSenior Vice President of OperationsMr. Ronald Evan Holtz CPA (Age 66)Ph.D., Executive Vice President of Administration Comp: $649.38kMr. Sean MenarguezDirector of Investor RelationsMr. David SandovalSenior Vice President & General CounselMr. Thomas Michael Ross (Age 63)Executive Vice President of Global Sales Mr. Jack HorganVice President of Corporate DevelopmentMs. Jill MayerSenior Vice President of Human ResourcesMore ExecutivesKey CompetitorsMeiraGTxNASDAQ:MGTXOmniAbNASDAQ:OABIAnaptysBioNASDAQ:ANABAbsciNASDAQ:ABSIHarvard BioscienceNASDAQ:HBIOView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCSold 5,406 shares on 4/18/2024Ownership: 0.273%Salem Investment Counselors Inc.Bought 28,741 shares on 4/11/2024Ownership: 0.054%John Joseph JohnstonSold 5,000 sharesTotal: $22,050.00 ($4.41/share)PNC Financial Services Group Inc.Bought 6,255 shares on 3/22/2024Ownership: 0.006%Cadian Capital Management LPBought 5,644,898 shares on 2/14/2024Ownership: 5.427%View All Insider TransactionsView All Institutional Transactions MXCT Stock Analysis - Frequently Asked Questions Should I buy or sell MaxCyte stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MaxCyte in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MXCT shares. View MXCT analyst ratings or view top-rated stocks. What is MaxCyte's stock price target for 2024? 4 Wall Street analysts have issued 1-year target prices for MaxCyte's stock. Their MXCT share price targets range from $7.00 to $11.00. On average, they anticipate the company's stock price to reach $8.67 in the next year. This suggests a possible upside of 128.1% from the stock's current price. View analysts price targets for MXCT or view top-rated stocks among Wall Street analysts. How have MXCT shares performed in 2024? MaxCyte's stock was trading at $4.70 on January 1st, 2024. Since then, MXCT shares have decreased by 19.1% and is now trading at $3.80. View the best growth stocks for 2024 here. When is MaxCyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our MXCT earnings forecast. How can I listen to MaxCyte's earnings call? MaxCyte will be holding an earnings conference call on Tuesday, May 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were MaxCyte's earnings last quarter? MaxCyte, Inc. (NASDAQ:MXCT) issued its quarterly earnings data on Tuesday, March, 12th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.05. The business had revenue of $15.67 million for the quarter, compared to the consensus estimate of $15.60 million. MaxCyte had a negative trailing twelve-month return on equity of 15.90% and a negative net margin of 91.85%. What guidance has MaxCyte issued on next quarter's earnings? MaxCyte updated its FY 2024 earnings guidance on Monday, March, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $29.6 million-$31.3 million, compared to the consensus revenue estimate of $42.1 million. When did MaxCyte IPO? MaxCyte (MXCT) raised $150 million in an IPO on Friday, July 30th 2021. The company issued 12,000,000 shares at a price of $11.50-$13.50 per share. Who are MaxCyte's major shareholders? MaxCyte's stock is owned by many different institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.27%) and Salem Investment Counselors Inc. (0.05%). Insiders that own company stock include Casdin Partners Master Fund, L, Douglas Doerfler, John Joseph Johnston, Richard Douglas and Thomas M Ross. View institutional ownership trends. How do I buy shares of MaxCyte? Shares of MXCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MXCT) was last updated on 4/23/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsGoldenCrest MetalsIs Tesla going out of business?DTI Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
